Jazz Pharmaceuticals plc — Form 10-Q
Filed November 2, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Renee D. Gala (CEO) and Philip L. Johnson (CFO) certified Jazz Pharmaceuticals' Q3 2026 Form 10-Q on November 2, 2026. The certifications attest that the financial statements fairly present the company's condition and cash flows, that disclosure controls and internal controls over financial reporting are effective, and that no material weaknesses or fraud were identified. These are standard Sarbanes-Oxley Section 302 and 906 attestations required for all public companies.
Why this rating
Routine quarterly SOX certification with no disclosed deficiencies; administrative and legally required filing with no business substance.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.